CHO Pharma
Rooted in glycoscience, CHO PHARMA is committed to developing first-in-class and best-in-class therapeutics for patients with high unmet needs. We have developed a suite of proprietary ADC technologies designed to address the key limitations of conventional ADCs. Our CHOptimaxTM glycoengineering platform, combined with an innovative linker design, enables the efficient, robust and cost-effective production of glycosite-specific ADCs. The platform offers enhanced conjugation stability, broad payload flexibility and an improved therapeutic window. CHOptimaxTM also supports next-generation antibody-conjugate architectures, including dual-payload ADCs, antibody-X conjugates and bispecific ADCs designs, thereby expanding therapeutic versatility and opening new avenue for treatment possibilities.
